-
Edgewise Therapeutics NASDAQ:EWTX Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
Location: | Website: edgewisetx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.259B
Cash
511.8M
Avg Qtr Burn
-25.9M
Short % of Float
14.77%
Insider Ownership
0.47%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EDG-5506 Details Becker Muscular Dystrophy | Phase 2 Data readout | |
Phase 2 Data readout | ||
EDG-5506 Details Rare diseases, Duchenne muscular dystrophy | Phase 2 Data readout | |
EDG-5506 Details Rare diseases, Limb-Girdle Muscular Dystrophy, McArdle disease | Phase 2 Update | |
EDG-5506 Details Duchenne muscular dystrophy, Rare diseases | Phase 2 Update | |
Sevasemten (EDG-5506) Details Becker Muscular Dystrophy | Phase 1b Update | |
EDG-7500 Details Hypertrophic cardiomyopathies , Heart disease | Phase 1 Data readout |